← Back to Screener
C4 Therapeutics, Inc. (CCCC)
Price$4.38
Value ScoreC
Growth ScoreD
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)67.68%
Price vs S&P 500 (4W)44.69%
VGM Score54.80
Market Capitalization$483.18M
All Metrics
Book Value / Share (Quarterly)$2.25
P/TBV (Annual)0.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)4.95%
Cash Flow / Share (Quarterly)$-0.92
Price vs S&P 500 (YTD)117.86%
Net Profit Margin (TTM)-297.76%
EPS (TTM)$-1.18
10-Day Avg Trading Volume2.31M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)1.60%
EPS (Annual)$-1.27
ROI (Annual)-40.92%
Net Profit Margin (5Y Avg)-364.35%
Cash / Share (Quarterly)$2.27
Revenue Growth QoQ (YoY)-15.00%
ROA (Last FY)-29.24%
Revenue Growth TTM (YoY)-12.37%
EBITD / Share (TTM)$-1.16
ROE (5Y Avg)-41.87%
Operating Margin (TTM)-326.56%
Cash Flow / Share (Annual)$-1.02
P/B Ratio2.06x
P/B Ratio (Quarterly)1.10x
Net Income / Employee (Annual)$-1,009,600
EV / Revenue (TTM)12.10x
Net Interest Coverage (TTM)-46.66x
ROA (TTM)-33.22%
EPS Incl Extra (Annual)$-1.27
Current Ratio (Annual)7.81x
Quick Ratio (Quarterly)8.75x
3-Month Avg Trading Volume2.55M
52-Week Price Return231.06%
Revenue / Employee (TTM)$335,200
Tangible BV / Share (Quarterly)$4.39
P/S Ratio (Annual)13.44x
Asset Turnover (Annual)0.10x
52-Week High$4.58
Operating Margin (5Y Avg)-385.07%
EPS Excl Extra (Annual)$-1.27
CapEx CAGR (5Y)-1.36%
26-Week Price Return83.61%
Quick Ratio (Annual)7.60x
13-Week Price Return57.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.00x
Enterprise Value$421.90M
Revenue / Share Growth (5Y)-10.87%
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)-16.48%
Revenue / Employee (Annual)$345,600
Pretax Margin (Annual)-291.74%
Cash / Share (Annual)$2.56
3-Month Return Std Dev103.84%
Net Income / Employee (TTM)$-998,100
ROE (Last FY)-40.92%
Net Interest Coverage (Annual)-88.52x
EPS Basic Excl Extra (Annual)$-1.27
Receivables Turnover (TTM)6.39x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)13.06x
ROI (TTM)-50.68%
P/S Ratio (TTM)13.86x
Pretax Margin (5Y Avg)-362.97%
Revenue / Share (Annual)$0.43
Tangible BV / Share (Annual)$5.91
Price vs S&P 500 (52W)202.85%
Year-to-Date Return128.80%
5-Day Price Return22.75%
EPS Normalized (Annual)$-1.27
ROA (5Y Avg)-28.17%
Net Profit Margin (Annual)-292.08%
Month-to-Date Return54.42%
Cash Flow / Share (TTM)$-2.71
EBITD / Share (Annual)$-1.37
Operating Margin (Annual)-320.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-41.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)0.35x
P/B Ratio (Annual)0.72x
Pretax Margin (TTM)-297.41%
Book Value / Share (Annual)$2.65
Price vs S&P 500 (13W)47.45%
Beta2.92x
P/FCF (Annual)8.90x
Revenue / Share (TTM)$0.28
ROE (TTM)-50.68%
52-Week Low$1.21
vGradeC
gGradeD
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.20est. -0.38
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CCCCC4 Therapeutics, Inc. | C | D | A | $4.38 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies designed to address difficult-to-treat cancers and other diseases. Its proprietary TORPEDO platform enables the efficient design of small-molecule degraders that leverage the body's natural protein recycling system to overcome drug resistance and tackle undruggable targets. The company's pipeline includes three oncology programs: Cemsidomide, CFT1946, and CFT8919.